Today's Rundown Novartis to move U.K. headquarters to London’s White City Brexit ‘could be an opportunity for U.K. clinical research’ Alkermes eyes 2019 filing as schizophrenia drug hits the mark in phase 3 [Sponsored] Minimal Residual Disease: Application in Blood Cancers ViaCyte bags $80M to trial diabetes stem cell therapies Inflazome brings on ex-Novartis executive as CMO after €40M VC round Biohaven sets up Shanghai outpost to handle Asia-Pacific portfolio Blaze Bioscience kicks off pivotal trial for brain tumor-illumination tech Featured Story | | | Thursday, November 29, 2018 Novartis is set to move its U.K. headquarters to London. The relocation will see Novartis set up in the White City Place development next to Imperial College London’s new campus. |
|
|
Top Stories Thursday, November 29, 2018 The U.K. has been punching below its weight in attracting clinical research, and Brexit could provide an opportunity to remedy that, according to an industry body. Thursday, November 29, 2018 Alkermes' schizophrenia drug met its primary endpoints in a second phase 3 trial, setting it up for an FDA filing in mid-2019. Patients taking the drug gained less weight on average than patients taking olanzapine, the antipsychotic on which it is based. Monday, November 26, 2018 A diagnosis of chronic lymphocytic leukemia (CLL) can mean a long road with many twists and turns as patients try to achieve long-term remission from this chronic, complex and progressive form of blood cancer. Thursday, November 29, 2018 ViaCyte has raised $80 million to continue clinical development of its cell therapy treatments for diabetes. The series D positions ViaCyte to generate phase 1/2 data on one candidate while working to get another back into the clinic. Thursday, November 29, 2018 Inflazome has brought on Thomas Jung, M.D., Ph.D., to be its new chief medical officer and lead clinical development of its NLRP3 inhibitors for inflammatory diseases. Thursday, November 29, 2018 Biohaven has created a wholly owned subsidiary in Shanghai. BioShin will develop and commercialize Biohaven’s migraine and neurology assets in China and other markets in the Asia-Pacific region. Wednesday, November 28, 2018 Blaze Bioscience has enrolled the first patient in a pivotal phase 2/3 trial of its scorpion venom-based “tumor paint,” a fluorescent molecule that homes in on cancer cells and illuminates them, making it easier for surgeons working to remove brain tumors. | This week's sponsor is Johnson & Johnson Innovation. | | | |
Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Patheon, part of Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Catalent In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion. Sponsored by: Catalent Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Sponsored by: Catalent What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Compliance Training for Professionals working in APAC region March 4-7, 2019 | Singapore FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA BioBasics: Biotech For The Non-Scientist December 5-6, 2018 | Boston, MA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami Molecular Medicine Tri-Conference March 10-15, 2019 | San Francisco, CA | 